The invention belongs to the field of biomedicines, and relates to an application of a hexokinase 2-specific inhibitor in the prevention and treatment of acute central nervous system injury diseases. The invention discovers for the first time that both the hexokinase 2-specific inhibitor and selective gene knockdown of hexokinase 2 can effectively reduce cerebral injuries caused by cerebral arterial embolisms in rats by inhibiting microglial cell-mediated neuroinflammation, indicating that various medicines for selectively inhibiting hexokinase 2 have a nerve protection effect.本發明屬於生物醫藥領域，係關於己糖激酶專一性抑制劑在防治急性中樞神經系統損傷疾病中的應用。本發明首次發現己糖激酶2專一性抑制劑以及選擇性基因敲低己糖激酶2均可透過抑制小神經膠質細胞所介導的神經發炎反應，有效減輕大鼠中大腦動脈梗塞所造成的腦損傷，其顯示各種選擇性抑制己糖激酶2的藥物具備神經保護作用。
